Aarti Pharmalabs Limited (AARTIPHARM) Share Price, Dividend & Analysis | Anvest

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Aarti Pharmalabs Limited is an Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates for various therapeutic areas. Operating primarily in India, it caters to both domestic and international markets within the specialty and generic drug segments.

Drug Manufacturers - Specialty & GenericFounded:2023CEO/MD:Rajendra V. GogriHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

Its primary products are APIs, Pharmaceutical Intermediates, and New Chemical Entities (56.50% of turnover), and Xanthine Derivatives (43.50% of turnover).

Revenue growth: -14.0%FY26 growth-2.2%3Y CAGR
EPS growth: -35.9%FY26 growth-3.4%3Y CAGR
CFO / PAT: 1.50×FY26

What Looks Strong

Cash FlowOperating cash flow was 1.50× total net profit in FY26.
MarketShareholder returns have comfortably outpaced the Nifty 500 benchmark over the 3-year period.
Balance SheetConservative capital structure with manageable leverage of 0.32× Debt/Equity.

What to Watch

RevenueRevenue declined about 14% in FY26 (consolidated: ₹2,115 cr → ₹1,819 cr). Watch whether the next results confirm a trend or a one-off.
EarningsNet profit fell about 36% in FY26 (consolidated: ₹272 cr → ₹175 cr). Watch margins and one-off items in the next filing.
MarginsOperating margin compressed from ~17.8% to ~14.6% in FY26 (consolidated). Watch input costs and pricing in the next two results.
ValuationShare price has risen ~31% annualised over three years against ~-4% profit growth, increasing valuation sensitivity to a growth slowdown.

Reports a single operating segment in its results filings.
It generates revenue by supplying these critical raw materials to pharmaceutical companies for the production of finished drug formulations, focusing on both patented and generic segments.
The company operates 15 plants, including 3 dedicated R&D facilities, and 3 offices nationally.

FY26 (consolidated): revenue ₹1,819 cr, down 14% from ₹2,115 cr in FY25; net profit ₹175 cr, down 36% from ₹272 cr in FY25.
FY26 (consolidated): operating cash flow ₹262 cr (1.5× net profit); debt/equity 0.32×.
Latest quarter to Sep 2026 (consolidated): revenue ₹610 cr (up 46% year on year); net profit ₹71.5 cr.